Notes: ICS: inhaled corticosteroids; LABA: ICS + long-acting
bete2-agonist; LTRA: Leukotriene receptor antagonists.
Results of optimal course comparison with other groups not using the
drug as controls are plotted in Figure 1, the ICS + LABA group showed a
significant improvement in cough at an early stage, particularly in the
4th week, the symptoms significantly improved; meanwhile, the symptoms
of ICS+LTRA and ICS groups were significantly improved at 36 weeks. LTRA
alone showed a significant improvement at 20 weeks. The safety analysis
results with group 1 as the control are shown in Table S4, all four
treatment regimens could reduce the risk of CVA recurrence and
progression to typical asthma. The effect of the LTRA group was the most
significant, followed by ICS and ICS+LABA groups, and then the ICS+LTRA
group.